Unusual Options Activity (MAR 24, 2007)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Stock Tickers: DNDN, OVTI, HAL, RRI, MEDX, CHS

Unusual Options Activity is something we like reviewing as we near the end of the quarter and as we near certain events.  There were several stocks that saw highly unusual options activity Friday (March 23) and we prefer tracking options later in the week because they often give weekend insight or speculation of a weekend or imminent event.

Dendreon (DNDN) saw 21,787 APR07 $5.00 PUTS and 18,008 APR07 $5.00 CALLS. With the FDA Panel review set for next week, this one is easily explananble.  The stock rose 13% and has been the talk of the biotech traders and message boards.  It is a battleground stock with massive short sellers betting it will flop and with a huge following of traders thinking and hoping the FDA Panel backs its prostate cancer vaccine.

Reliant Energy (RRI) MAY07 $20/$20 straddle: As Reliant re-nears profitability and is back from the throws of death after the Enron collapse, it appears someone is making a bet that it either sees further stock runs or that Reliant sees a complete reversal.  The stock gapped down Friday after Bank of America cut its rating to a Sell on valuations after a 100% rise in the last year.

Halliburton (HAL) saw more than 26,000 contracts go off in the April07 $40 CALLS.  Either someone is thinking someone may try to do a deal or they are hoping for a series of sudden fortunes.  Those are about 4 weeks to maturity and had an open interest of 243,941 contracts (24 million shares leveraged).  With the tender and repurchases it is hard to know what support will be there and hard to know what is making a trader think it will go up rapidly from $31+. In fairness there was a large offset in the Puts as well, so this could quite easily be a clean up of an older trader or just a remote hedging transaction.

OmniVision (OVTI) saw quite a bit of unusual options trading interest in numerous strike prices in numerous months.  Rumors were around on every chat room, after TheStreet.cm ran a story that Eastman Kodak (EK) may be interested, and after Barron’s covered it laste in the day.

Chicos FAS (CHS) is seeing renewed CALL buying of late as the company has been looking like its recent woes have at least seen the worst and may be improving.

Medarex (MEDX) saw some unusual options activity for the May calls on initiations of its psoriasis treatment starting Phase I trials Friday (news).  Psoriasis is one of the massive potential blockbuster drugs and/or creams because the condition is widespread and depending on the severity it is very under-treated compared to many less common disorders.  But the open interest in the JAN 2008 contracts is massive because of upcoming reviews late in 2007 (contract & open interest)
$12.50 CALLS 55,390
$15.00 CALLS 36,202
$17.50 CALLS 78,288
$7.50    PUTS 12,820
$10.00    PUTS 14,960
$12.50    PUTS 36,826
$15.00    PUTS 16,261

So these are all going to be some of the issues to watch as options often show a completely unique trading pattern based around future events.

Jon C. Ogg
March 24, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618